Back to Treatments

Treatment

Luspatercept (Reblozyl)

1
Conditions
4
Trials
700
Participants
60%
Average Safety

Condition Evidence

Thalassemias

4 trials · 700 participants

70% effectiveness · 60% safety
Luspatercept (Reblozyl) | DFDA